NeoVax Plus Nivolumab: What a Phase 1 Ovarian Cancer Trial Can and Cannot SayBy Sergio RuizOctober 16, 20260 A phase 1 trial of NeoVax with nivolumab in recurrent ovarian cancer showed feasibility, acceptable safety and immune responses. Why that is all it can show, for now.
